Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More clinical data required for iclaprim application:

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Arpida did not demonstrate efficacy of its anti-infective iclaprim for treatment of complicated skin and skin structure infections within an acceptable non-inferiority margin, FDA says in a "complete response" letter. An additional study showing non-inferiority of intravenous iclaprim to an approved comparator may be sufficient to meet this requirement, depending on study results, Arpida said Jan. 19. A resubmission will likely also provide updated safety data and labeling information. The letter was not a surprise, said CEO Jurgen Raths in a company release; a November advisory panel voted 17-2 against the drug's safety and efficacy (1"The Pink Sheet" DAILY, Nov. 20, 2008). Arpida slashed three-fourths of its workforce and will seek expert advice on further clinical development for iclaprim (2"The Pink Sheet," Dec. 22, 2008, In Brief)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS004045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel